Facebook Twitter LinkedIn Google Plus RSS

Soligenix gets orphan drug designation for radiation treatment

By ,

Princeton-based pharmaceutical company Soligenix announced today the Food and Drug Administration has granted it orphan drug designation for its acute radiation syndrome treatment, SGX94. The Office of Orphan Products Development granted the designation.

According to the announcement, in addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application, and certain tax credits.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy